Cynosure Promotes Doug Delaney To Chief Commercial Officer

Published: Nov 01, 2016

WESTFORD, Mass., Nov. 1, 2016 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), a leading developer and manufacturer of aesthetic treatment systems, today announced the promotion of Douglas J. Delaney, Executive Vice President of Worldwide Sales, to Chief Commercial Officer (CCO). In his new role, Mr. Delaney will lead all sales and revenue initiatives across the Company, including identifying new revenue sources and driving new opportunities for growth. He reports to Michael Davin, President and Chief Executive Officer.

Douglas J. Delaney has been promoted from Executive Vice President of Worldwide Sales at Cynosure, Inc. to the Company's Chief Commercial Officer. Cynosure, a global aesthetic device manufacturer headquartered in Massachusetts, made the announcement on Tuesday, November 1, 2016.

"Doug's leadership and experience in creating a world-class global sales organization at Cynosure, combined with the results he has achieved over his 13-year tenure, make him uniquely qualified to move into this new position," Mr. Davin said. "The performance of our direct sales force in North America, Asia and Europe is directly attributable to Doug's skill in business development, planning and execution, as well as his ability to build strong relationships with our customers and partners. As CCO, Doug's focus will expand to ensuring that all activities within the Company are aligned to meet our strategic commercial objectives. He has done an outstanding job in leading our sales team, and he will play a central role as we continue to deliver the highest quality products and services to our customers."

A seasoned executive with more than 25 years of experience in the aesthetic laser and medical equipment markets, Mr. Delaney joined Cynosure in 2003 as Director of North American Sales.  He became Vice President of North American Sales in 2004 and was promoted to Executive Vice President of Sales in 2005. In June 2013, Mr. Delaney was promoted to Executive Vice President of Worldwide Sales. Before joining Cynosure, he was national sales manager at Cutera, Inc.

About Cynosure, Inc.
Cynosure develops, manufactures, and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through non-invasive and minimally invasive laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecological health. Cynosure also markets radiofrequency energy-sourced medical devices for precision surgical applications such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, Q-switched lasers, intense pulsed light and radiofrequency technology. Cynosure sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.  For corporate or product information, visit Cynosure's website at

Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of the federal securities laws, about our business prospects and management transition. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "plans," "intends," "expects," "goals" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Our future results may differ materially from our past results and from those projected in the forward-looking statements due to various uncertainties and risks, including, but not limited to, those described in Item 1A of Part II (Risk Factors) of our Quarterly Report on Form 10-Q for the three months ended June 30, 2016. The forward-looking statements speak only as of the date of this press release and undue reliance should not be placed on these statements. We disclaim any obligation to update any forward-looking statements contained herein after the date of this press release.


Scott Solomon
Senior Vice President
Sharon Merrill Associates, Inc.

Photo -

To view the original version on PR Newswire, visit:

SOURCE Cynosure, Inc.

Back to news